Mantle Cell Lymphoma | Specialty

Dr. Davids on Rationale for Ibrutinib/Umbralisib Combo in R/R CLL and MCL

July 6th 2020

Matthew S. Davids, MD, MMSc, discusses the rationale for examining ibrutinib in combination with umbralisib in relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.

Dr. Ruan on the Utility of Molecular Profiling in Mantle Cell Lymphoma

June 30th 2020

Jia Ruan, MD, PhD, discusses ​the utility of molecular profiling in mantle cell lymphoma.

Dr. Roué on the Synergistic Activity With TG-1701, Ublituximab, and Umbralisib in MCL

June 30th 2020

Gaël Roué, PhD, discusses the synergistic activity with TG-1701, ublituximab, and umbralisib in ibrutinib-resistant mantle cell lymphoma models.

Wang Weighs in on Promising Pharmacological Profile of KTE-X19 in High- and Low-Risk MCL

June 30th 2020

Michael Wang, MD, further discusses data regarding the pharmacological profile of KTE-X19, the significance of these findings, and the next steps for this research.

Dr. Wang on the Efficacy of KTE-X19 in Low- and High-Risk R/R MCL

June 26th 2020

Michael Wang, MD, discusses the efficacy of KTE-X19 in low- and high-risk patients with relapsed/refractory mantle cell lymphoma as part of the phase 2 ZUMA-2 trial.

Dr. Karmali on Optimizing Maintenance Therapy in Older Patients With MCL

June 24th 2020

Reem Karmali, MD, MS, discusses next steps for optimizing maintenance therapy in older patients with mantle cell lymphoma.

Dr. Jain on Future Research Efforts Examining Venetoclax Resistance Patterns in MCL

June 24th 2020

Preetesh Jain, MD, PhD, discusses research efforts examining resistance patterns with venetoclax in mantle cell lymphoma.

Future Directions in Mantle Cell Lymphoma

June 24th 2020

ASCO 2020: ZUMA-2 Update

June 24th 2020

Bruton Tyrosine Kinase Inhibitors

June 24th 2020

A Look at ZUMA-2 Trial

June 24th 2020

An Introduction to Mantle Cell Lymphoma & KTE-X19

June 24th 2020

Dr. Lee on B-Cell Receptor Targeting in Relapsed/Refractory MCL

June 23rd 2020

Hun Ju Lee, MD, discusses B-cell receptor targeting in relapsed/refractory mantle cell lymphoma.

Suggested Benefit of Novel BTK Inhibitor Observed in MCL Models and in NHL Combo Regimen

June 23rd 2020

In preclinical models, the novel irreversible BTK inhibitor TG-1701 demonstrated similar activity to ibrutinib in mantle cell lymphoma cell lines and showed additive benefit when combined with ublituximab and umbralisib in non-Hodgkin lymphoma model.

Dr. Wang on Comparative Analysis of KTE-X19 in Higher- Versus Lower-Risk R/R MCL

June 22nd 2020

Michael Wang, MD, discusses the objectives of a comparative analysis of the phase 2 ZUMA-2 trial with KTE-X19 in patients with mantle cell lymphoma.

Dr. Wang on the Safety and Efficacy of KTE-X19 in R/R MCL

June 20th 2020

Michael Wang, MD, discusses the safety and efficacy of KTE-X19 in relapsed/refractory mantle cell lymphoma.

Dr. Karmali on Treating Older Patients With MCL in the Rituximab Era

June 16th 2020

Reem Karmali, MD, MS, discusses an analysis examining clinical outcomes and predictors of survival in older patients with mantle cell lymphoma in the era of rituximab.

Cirmtuzumab Plus Ibrutinib Shows Activity and Tolerability in MCL and CLL

June 16th 2020

Hun Ju Lee, MD, discusses the interim results of a study examining cirmtuzumab plus ibrutinib and the next steps with this research in mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Maintenance Rituximab Improves Survival in Older Patients With MCL, But More Work Needed

June 16th 2020

Reem Karmali, MD, discusses survival outcomes in older patients with MCL with maintenance rituximab and highlights other ongoing MCL research efforts to optimize maintenance strategies in this patient population.

Dr. Karmali on the Importance of Evaluating Older Patients With MCL in the Rituximab Era

June 10th 2020

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.